Agilent Technologies (NYSE:A) PT Raised to $161.00 at Robert W. Baird

Agilent Technologies (NYSE:AGet Rating) had its target price boosted by Robert W. Baird from $155.00 to $161.00 in a research note released on Wednesday morning, The Fly reports. The brokerage currently has an outperform rating on the medical research company’s stock.

A has been the topic of a number of other research reports. Evercore ISI dropped their price target on Agilent Technologies from $170.00 to $155.00 and set an outperform rating on the stock in a research note on Wednesday, February 23rd. Stifel Nicolaus dropped their price target on Agilent Technologies from $169.00 to $145.00 and set a hold rating on the stock in a research note on Wednesday, February 23rd. Truist Financial lowered Agilent Technologies from a buy rating to a hold rating in a report on Tuesday, April 19th. Bank of America decreased their price objective on Agilent Technologies from $179.00 to $160.00 and set a buy rating on the stock in a report on Wednesday, February 23rd. Finally, Wells Fargo & Company decreased their price objective on Agilent Technologies from $160.00 to $130.00 and set an equal weight rating on the stock in a report on Monday, April 25th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Buy and a consensus target price of $163.92.

Shares of Agilent Technologies stock opened at $130.55 on Wednesday. Agilent Technologies has a 12-month low of $112.64 and a 12-month high of $179.57. The stock has a market cap of $39.21 billion, a P/E ratio of 33.13, a P/E/G ratio of 2.80 and a beta of 1.06. The company has a quick ratio of 1.64, a current ratio of 2.19 and a debt-to-equity ratio of 0.53. The business’s 50 day moving average is $126.40 and its 200-day moving average is $138.54.

Agilent Technologies (NYSE:AGet Rating) last announced its quarterly earnings data on Tuesday, May 24th. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.01. Agilent Technologies had a return on equity of 27.04% and a net margin of 18.70%. The company had revenue of $1.61 billion for the quarter, compared to analysts’ expectations of $1.62 billion. During the same quarter in the prior year, the business posted $0.97 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. On average, sell-side analysts expect that Agilent Technologies will post 4.86 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 27th. Stockholders of record on Tuesday, July 5th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Friday, July 1st. Agilent Technologies’s dividend payout ratio (DPR) is currently 21.32%.

In related news, SVP Michael Tang sold 1,210 shares of the firm’s stock in a transaction dated Friday, March 18th. The stock was sold at an average price of $136.21, for a total value of $164,814.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

A number of institutional investors have recently bought and sold shares of A. Ironwood Wealth Management LLC. raised its position in Agilent Technologies by 142.5% in the second quarter. Ironwood Wealth Management LLC. now owns 485 shares of the medical research company’s stock valued at $72,000 after purchasing an additional 285 shares during the last quarter. Morgan Stanley raised its position in Agilent Technologies by 2.9% in the second quarter. Morgan Stanley now owns 1,154,775 shares of the medical research company’s stock valued at $170,688,000 after purchasing an additional 33,059 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in Agilent Technologies by 5.1% in the third quarter. Mercer Global Advisors Inc. ADV now owns 9,838 shares of the medical research company’s stock valued at $1,550,000 after purchasing an additional 476 shares during the last quarter. Bank of Nova Scotia raised its position in Agilent Technologies by 9.4% in the third quarter. Bank of Nova Scotia now owns 50,570 shares of the medical research company’s stock valued at $7,966,000 after purchasing an additional 4,325 shares during the last quarter. Finally, Vident Investment Advisory LLC raised its position in Agilent Technologies by 11.0% in the third quarter. Vident Investment Advisory LLC now owns 15,669 shares of the medical research company’s stock valued at $2,469,000 after purchasing an additional 1,558 shares during the last quarter.

About Agilent Technologies (Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Featured Articles

The Fly logo

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.